Cargando…

Combination chemotherapy with epirubicin, docetaxel and cisplatin (EDP) in metastatic or recurrent, unresectable gastric cancer

Based on single agent activities and the additive or synergistic effects of three individual drugs in gastric cancer, we performed a phase II study of a new regimen combining epirubicin, docetaxel and cisplatin (EDP) for unresectable gastric cancer. The patients with histologically confirmed metasta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, S-H, Kang, W K, Park, J, Kim, H Y, Kim, J H, Lee, S I, Park, J O, Kim, K, Jung, C W, Park, Y S, Im, Y-H, Lee, M H, Park, K
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2004
Materias:	Clinical
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364756/ https://www.ncbi.nlm.nih.gov/pubmed/15188010 http://dx.doi.org/10.1038/sj.bjc.6601891

Ejemplares similares

Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer
por: Kim, S T, et al.
Publicado: (2005)

Phase I study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer
por: Takayama, T, et al.
Publicado: (2007)

Docetaxel (Taxotere), cisplatin, UFT, and leucovorin combination chemotherapy in advanced gastric cancer
por: Oh, S C, et al.
Publicado: (2005)

Phase II study of docetaxel and irinotecan combination chemotherapy in metastatic gastric carcinoma
por: Park, S R, et al.
Publicado: (2006)

Weekly etoposide, epirubicin, cisplatin, 5-fluorouracil and leucovorin: an effective chemotherapy in advanced gastric cancer.
por: Chi, K. H., et al.
Publicado: (1998)

A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer
por: Lee, J-L, et al.
Publicado: (2008)

Phase I/II study of S-1 combined with weekly docetaxel in patients with metastatic gastric carcinoma
por: Park, S R, et al.
Publicado: (2008)

Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum
por: Yi, J H, et al.
Publicado: (2012)

Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal Cancer
por: Kim, Miso, et al.
Publicado: (2017)

Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcinoma
por: Lee, S, et al.
Publicado: (2010)

Multicenter phase II study of docetaxel plus oxaliplatin combination chemotherapy in patients with advanced gastric cancer: Daegu Gyeongbuk Oncology Group
por: Kim, J G, et al.
Publicado: (2008)

A Multicenter Randomized Phase II Study of Docetaxel vs. Docetaxel Plus Cisplatin vs. Docetaxel Plus S-1 as Second-Line Chemotherapy in Metastatic Gastric Cancer Patients Who Had Progressed after Cisplatin Plus Either S-1 or Capecitabine
por: Lee, Keun-Wook, et al.
Publicado: (2017)

CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients
por: Park, S R, et al.
Publicado: (2011)

Methotrexate, vinblastine, doxorubicin and cisplatin combination regimen as salvage chemotherapy for patients with advanced or metastatic transitional cell carcinoma after failure of gemcitabine and cisplatin chemotherapy
por: Han, K S, et al.
Publicado: (2008)

A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer
por: Park, Y H, et al.
Publicado: (2004)

Third-line docetaxel chemotherapy for recurrent and metastatic gastric cancer
por: Lee, Ji Hyun, et al.
Publicado: (2013)

The beneficial effect of palliative resection in metastatic colorectal cancer
por: Park, J H, et al.
Publicado: (2013)

Adenosine triphosphate-based chemotherapy response assay-guided chemotherapy in unresectable colorectal liver metastasis
por: Hur, H, et al.
Publicado: (2012)

Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib
por: Kang, Y-K, et al.
Publicado: (2013)

Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours
por: Ahn, H K, et al.
Publicado: (2013)

Clinical outcome and predictive factors for docetaxel and epirubicin neoadjuvant chemotherapy of locally advanced breast cancer
por: Won, Hye Sung, et al.
Publicado: (2020)

Potential role of CMPK1, SLC29A1, and TLE4 polymorphisms in gemcitabine-based chemotherapy in HER2-negative metastatic breast cancer patients: pharmacogenetic study results from the prospective randomized phase II study of eribulin plus gemcitabine versus paclitaxel plus gemcitabine (KCSG-BR-13-11)
por: Cho, E.H., et al.
Publicado: (2021)

Myelomatous effusion with poor response to chemotherapy.
por: Kim, Y. M., et al.
Publicado: (2000)

A phase II study of weekly docetaxel and cisplatin plus oral tegafur/uracil and leucovorin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer
por: Li, C-P, et al.
Publicado: (2010)

Adjuvant chemotherapy for gastric cancer: a randomised phase 3 trial of mitomycin-C plus either short-term doxifluridine or long-term doxifluridine plus cisplatin after curative D2 gastrectomy (AMC0201)
por: Kang, Y-K, et al.
Publicado: (2013)

Prognostic implication of mucinous histology in colorectal cancer patients treated with adjuvant FOLFOX chemotherapy
por: Lee, D-W, et al.
Publicado: (2013)

Cost accounting in the EDP-supported chemical laboratory
por: Gibitz, H. J.
Publicado: (1983)

Efficacy and safety of cisplatin and weekly docetaxel in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
por: Kim, Moon Jin, et al.
Publicado: (2019)

A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer
por: Lim, S H, et al.
Publicado: (2015)

Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin.
por: Hilkens, P. H., et al.
Publicado: (1997)

Phase II study of capecitabine and cisplatin as first-line combination therapy in patients with gastric cancer recurrent after fluoropyrimidine-based adjuvant chemotherapy
por: Kang, H J, et al.
Publicado: (2005)

Combination chemotherapy of oral 5'-deoxy-5-fluorouridine and cisplatin in advanced gastric cancer: a phase II study.
por: Ahn, M. J., et al.
Publicado: (1998)

Gemcitabine–oxaliplatin plus prednisolone is active in patients with castration-resistant prostate cancer for whom docetaxel-based chemotherapy failed
por: Lee, J-L, et al.
Publicado: (2014)

Phase II study of a trastuzumab biosimilar in combination with paclitaxel for HER2-positive recurrent or metastatic urothelial carcinoma: KCSG GU18-18
por: Kim, M., et al.
Publicado: (2023)

Biomarker analysis in stage III–IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival
por: Kim, J-S, et al.
Publicado: (2009)

Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicenter retrospective study of the Korean Cancer Study Group (KCSG)
por: Park, H.S., et al.
Publicado: (2021)

Phase II Study of Induction Chemotherapy with Docetaxel, Capecitabine, and Cisplatin Plus Bevacizumab for Initially Unresectable Gastric Cancer with Invasion of Adjacent Organs or Paraaortic Lymph Node Metastasis
por: Kim, Jwa Hoon, et al.
Publicado: (2018)

Modified Epirubicin, cisplatin, and 5-FU regimen as first-line chemotherapy in metastatic gastric or gastroesophageal junction adenocarcinoma: A Phase II study
por: Babu, K. Govind, et al.
Publicado: (2019)

Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for advanced gastric carcinoma.
por: Cho, Eun Kyung, et al.
Publicado: (2002)

RRM1 Expression as a Prognostic Biomarker for Unresectable or Recurrent Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin
por: Chun, Jung Won, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_78eu908qukjue2ibl6me2jjsoo